Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models.
Jaline BroquezaChandra B PrabaharanKevin J H AllenRubin JiaoDarrell R FisherRyan DickinsonValerie MacDonald-DickinsonMaruti UppalapatiEkaterina DadachovaPublished in: Pharmaceuticals (Basel, Switzerland) (2021)
Lu-IF3 targeting IGF2R on experimental canine OS tumors effectively decreases tumor growth. However, because of the limitations of murine models, careful evaluation of the possible toxicity of this treatment should be performed via nuclear imaging and image-based dosimetry in healthy dogs before clinical trials in companion dogs with OS can be attempted.
Keyphrases
- clinical trial
- cancer therapy
- high resolution
- binding protein
- pi k akt
- deep learning
- growth hormone
- type diabetes
- metabolic syndrome
- radiation therapy
- adipose tissue
- mass spectrometry
- combination therapy
- young adults
- drug delivery
- skeletal muscle
- insulin resistance
- study protocol
- phase ii
- replacement therapy
- wild type
- photodynamic therapy
- fluorescence imaging
- oxide nanoparticles